Evolution of the Average Target: Incyte Corporation

Evolution of the Target Price: Incyte Corporation

Changes in Analyst Recommendations: Incyte Corporation

c4fb4fa0213d.S2hA67dkiVFJGlV42Z3yuMEZHPQhaNTDenPRhBVyCyU.ByM6rMQB-mlxQ2FNgKiWgaVuT65nHrepORultEcbMhAsGwvbhRfDHgZMMg~3fd73209943f78e01a88279d6c3d2f92
08-20 Canaccord Genuity Initiates Incyte at Buy With $152 Price Target MT
08-17 Piper Sandler Adjusts Price Target on Incyte to $130 From $110, Maintains Overweight Rating MT
08-13 Bernstein Adjusts Price Target on Incyte to $104 From $99, Keeps Market Perform Rating MT
08-03 Mizuho Adjusts Price Target on Incyte to $137 From $121 MT
08-03 Leerink Partners Adjusts Price Target on Incyte to $155 From $131, Maintains Outperform Rating MT
07-31 Argus Adjusts Price Target on Incyte to $140 From $115, Maintains Buy Rating MT
07-30 JPMorgan Adjusts Price Target on Incyte to $120 From $110, Maintains Neutral Rating MT
07-29 Incyte's Solid Q2 Seen Funding Strategy Beyond Jakafi Patent Expiration, RBC Says MT
07-29 TD Cowen Adjusts Incyte Price Target to $138 From $124, Maintains Buy Rating MT
07-29 Barclays Adjusts Incyte Price Target to $139 From $134, Maintains Overweight Rating MT
07-29 Morgan Stanley Adjusts Incyte PT to $119 From $104, Maintains Equal Weight Rating MT
07-29 BMO Capital Adjusts Incyte Price Target to $130 From $112, Maintains Market Perform Rating MT
07-29 Jefferies & Co Adjusts Incyte Price Target to $115 From $105, Maintains Hold Rating MT
07-29 Guggenheim Adjusts Incyte Price Target to $150 From $136, Maintains Buy Rating MT
07-29 HC Wainwright Raises Incyte Price Target to $150 From $140, Maintains Buy Rating MT
07-29 Goldman Sachs Adjusts Incyte Price Target to $118 From $110, Maintains Neutral Rating MT
07-29 RBC Raises Price Target on Incyte to $109 From $99, Keeps Sector Perform Rating MT
07-28 Oppenheimer Raises Incyte Price Target to $120 From $107 MT
07-28 Stifel Raises Incyte Price Target to $145 From $123, Buy Rating Kept MT
07-28 Wells Fargo Adjusts Price Target on Incyte to $116 From $101 MT
07-23 JPMorgan Adjusts Price Target on Incyte to $110 From $105, Maintains Neutral Rating MT
07-22 Morgan Stanley Adjusts Price Target on Incyte to $104 From $103, Maintains Equalweight Rating MT
07-20 Goldman Sachs Adjusts Price Target on Incyte to $110 From $100, Maintains Neutral Rating MT
07-15 BofA Securities Raises Incyte Price Target to $136 From $124 MT
07-14 Barclays Adjusts Incyte Price Target to $134 From $117, Maintains Overweight Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-0.54%
+0.77%
-37.03%
-3.1%
+26.9%
+28.67%
+8.67%
+16.58%
+8.17%
+16.27%
Average +6.54%
Weighted average by Cap. +3.83%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
127.81USD
Average target price
127.12USD
Spread / Average Target
-0.54%
High Price Target
155.00USD
Spread / Highest target
+21.27%
Low Price Target
86.00USD
Spread / Lowest Target
-32.71%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Canaccord Genuity
Piper Sandler
Bernstein
Mizuho Securities
Leerink Partners
Argus
JPMorgan Chase
Barclays
RBC Capital Markets
Goldman Sachs
HC Wainwright
Guggenheim
Jefferies & Co.
BMO Capital
Morgan Stanley
TD Cowen
Oppenheimer
Stifel Nicolaus
Wells Fargo Securities
BofA Securities
UBS
Truist Securities
William O'Neil & Co
Evercore ISI
Deutsche Bank Securities
Wolfe Research
Citigroup
William Blair & Co.
JMP Securities
SVB Securities LLC
Morningstar
Cowen
SVB Leerink
Benchmark Capital
Credit Suisse
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
127.81USD
Average target price
127.12USD
Spread / Average Target
-0.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock
  4. Consensus Incyte Corporation